<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 17 )*
------
ABBOTT LABORATORIES
----------------------------------
(Name of Issuer)
COMMON SHARES WITHOUT PAR VALUE
----------------------------------
(Title of Class of Securities)
002824 10 0
----------------------------------
(CUSIP Number)
Check the following box if a fee is being paid with this statement / /. (A
fee is not required only if the filing person: (1) has a previous statement on
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
(Continued on following page(s))
Page 1 of 7 Pages
---
<PAGE>
CUSIP No. 002824 10 0 13G Page 2 of 7 Pages
----------- --- ---
- -------------------------------------------------------------------------------
(1) Name of Reporting Person. S.S. or I.R.S. Identification No. of Above
Person
Abbott Laboratories Stock Retirement Trust
I.R.S. Identification No. 36-6047554
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group* (b) /X/
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Citizenship or Place of Organization
Illinois
- -------------------------------------------------------------------------------
Number of Shares (5) Sole Voting Power
Beneficially 0
Owned by --------------------------------------------------
Each Reporting (6) Shared Voting Power
Person With 64,166,248
--------------------------------------------------
(7) Sole Dispositive Power
0
--------------------------------------------------
(8) Shared Dispositive Power
64,166,248
- -------------------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
64,166,248
- -------------------------------------------------------------------------------
(10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares*
X
- -------------------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
8.2%
- -------------------------------------------------------------------------------
(12) Type of Reporting Person*
EP
- -------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 002824 10 0 13G Page 3 of 7 Pages
----------- --- ---
- -------------------------------------------------------------------------------
(1) Name of Reporting Person. S.S. or I.R.S. Identification No. of Above
Person
Gary P. Coughlan
###-##-####
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group* (b) /X/
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Citizenship or Place of Organization
United States
- -------------------------------------------------------------------------------
Number of Shares (5) Sole Voting Power
Beneficially 66,504 shares - (Does not include shares
Owned by direct held in the Abbott
Each Reporting Laboratories Stock
Person With Retirement Trust for the
benefit of the reporting
person.)
--------------------------------------------------
(6) Shared Voting Power
64,166,248 shares - as Trustee, Abbott
Laboratories Stock
Retirement Trust.
--------------------------------------------------
(7) Sole Dispositive Power
66,504 shares (see note in 5 above)
direct
--------------------------------------------------
(8) Shared Dispositive Power
64,166,248 as Trustee, Abbott
Laboratories Stock
Retirement Trust.
- -------------------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
64,366,970 (Total of 5 + 6 + 134,218 shares - right to acquire by
exercise of stock options.)
- -------------------------------------------------------------------------------
(10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares*
- -------------------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
8.2%
- -------------------------------------------------------------------------------
(12) Type of Reporting Person*
IN
- -------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 002824 10 0 13G Page 4 of 7 Pages
----------- --- ---
- -------------------------------------------------------------------------------
(1) Name of Reporting Person. S.S. or I.R.S. Identification No. of Above
Person
Thomas C. Freyman
###-##-####
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group* (b) /X/
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Citizenship or Place of Organization
United States
- -------------------------------------------------------------------------------
Number of Shares (5) Sole Voting Power
Beneficially 22,242 shares - (Does not include shares
Owned by direct held in the Abbott
Each Reporting Laboratories Stock
Person With Retirement Trust for the
benefit of the reporting
person.)
--------------------------------------------------
(6) Shared Voting Power
64,166,248 shares - as Trustee, Abbott
Laboratories Stock
Retirement Trust.
--------------------------------------------------
(7) Sole Dispositive Power
22,242 shares (see note 5 above)
--------------------------------------------------
(8) Shared Dispositive Power
64,166,248 as Trustee, Abbott
Laboratories Stock
Retirement Trust.
- -------------------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
64,218,258 (Total of 5 + 6 + 29,768 shares - right to acquire by
exercise of stock options.)
- -------------------------------------------------------------------------------
(10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares*
- -------------------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
8.2%
- -------------------------------------------------------------------------------
(12) Type of Reporting Person*
IN
- -------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 002824 10 0 13G Page 5 of 7 Pages
----------- --- ---
- -------------------------------------------------------------------------------
(1) Name of Reporting Person. S.S. or I.R.S. Identification No. of Above
Person
Ellen M. Walvoord
###-##-####
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group* (b) /X/
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Citizenship or Place of Organization
United States
- -------------------------------------------------------------------------------
Number of Shares (5) Sole Voting Power
Beneficially 20,850 shares - (Does not include shares
Owned by direct held in the Abbott
Each Reporting Laboratories Stock
Person With Retirement Trust for the
benefit of the reporting
person.)
--------------------------------------------------
(6) Shared Voting Power
64,166,248 shares - as Trustee, Abbott
Laboratories Stock
Retirement Trust.
--------------------------------------------------
(7) Sole Dispositive Power
20,850 shares (see note in 5 above)
--------------------------------------------------
(8) Shared Dispositive Power
64,166,248 shares - as Trustee, Abbott
Laboratories Stock
Retirement Trust.
- -------------------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
64,226,970 (Total of 5 + 6 + 39,872 shares - right to acquire by
exercise of stock options.)
- -------------------------------------------------------------------------------
(10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares*
- -------------------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
8.2%
- -------------------------------------------------------------------------------
(12) Type of Reporting Person*
IN
- -------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
Item 1(a) Name of Issuer:
Abbott Laboratories
Item 1(b) Address of Issuer's Principal Executive Offices:
100 Abbott Park Road
Abbott Park, Illinois 60064-3500
Item 2(a) Name of Persons Filing:
Abbott Laboratories Stock Retirement Trust
Gary P. Coughlan
Thomas C. Freyman
Ellen M. Walvoord
Item 2(b) Address of Principal Business Office:
100 Abbott Park Road
Abbott Park, Illinois 60064-3500
Item 2(c) Citizenship:
Abbott Laboratories Stock Retirement Trust - Illinois.
Gary P. Coughlan, Thomas C. Freyman, and
Ellen M. Walvoord - United States
Item 2(d) Title of Class of Securities:
Common shares without par value
Item 2(e) CUSIP Number:
002824 10 0
Item 3 If this statement is filed pursuant to Rules 13d-1(b) or 13d-
2(b), check whether the person filing is an:
[x] Employee Benefit Plan, Pension Fund which is subject to the
provisions of the Employee Retirement Income Security Act of
1974.
Item 4 Ownership
(a) (see cover pages 2, 3,
(b) 4 and 5, Items 5 through
(c) 9 and 11.)
Item 5. Ownership of Five Percent or Less of a Class
Not applicable.
Page 6 of 7 pages
<PAGE>
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
The shares owned by the Abbott Laboratories Stock Retirement
Trust and the dividends thereon are held for the benefit of
participants of the Abbott Laboratories Stock Retirement Plan
pursuant to terms of that Plan and the Trust. The Abbott
Laboratories Stock Retirement Plan is a qualified profit sharing
plan. As of December 31, 1995, there were 36,248 participants
with share balances in the Plan.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding
Company.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certification.
Not applicable.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
This statement is filed on behalf of each individual listed below pursuant to
their agreement.
February 9, 1996
---------------------------------------
Date
/s/ Gary P. Coughlan
- --------------------------------- ABBOTT LABORATORIES STOCK
Gary P. Coughlan RETIREMENT TRUST
/s/ Thomas C. Freyman
- ---------------------------------
Thomas C. Freyman
/s/ Ellen M. Walvoord
- --------------------------------- /s/ Thomas C. Freyman
Ellen M. Walvoord --------------------------------------
Thomas C. Freyman, Chairman of
Trustees, Abbott Laboratories
Stock Retirement Trust
Page 7 of 7 pages
<PAGE>
DISCLAIMER OF BENEFICIAL OWNERSHIP
UNDER RULE 13d-4
The filing of Schedule 13G Amendment 17 on behalf of the Abbott Laboratories
Stock Retirement Trust does not constitute an admission that the undersigned is,
for purposes of Section 13(d) of the Securities and Exchange Act of 1934, the
beneficial owner of any securities covered by the Schedule. Pursuant to Rule
13d-4 of the Act, the undersigned disclaims such ownership with respect to any
shares listed therein of which he would not otherwise be deemed to be
beneficial owner.
/s/ Gary P. Coughlan
---------------------------------------
Gary P. Coughlan
February 9, 1996
---------------------------------------
Date
<PAGE>
DISCLAIMER OF BENEFICIAL OWNERSHIP
UNDER RULE 13d-4
The filing of Schedule 13G Amendment 17 on behalf of the Abbott Laboratories
Stock Retirement Trust does not constitute an admission that the undersigned is,
for purposes of Section 13(d) of the Securities and Exchange Act of 1934, the
beneficial owner of any securities covered by the Schedule. Pursuant to Rule
13d-4 of the Act, the undersigned disclaims such ownership with respect to any
shares listed therein of which he would not otherwise be deemed to be
beneficial owner.
/s/ Thomas C. Freyman
---------------------------------------
Thomas C. Freyman
February 9, 1996
---------------------------------------
Date
<PAGE>
DISCLAIMER OF BENEFICIAL OWNERSHIP
UNDER RULE 13d-4
The filing of Schedule 13G Amendment 17 on behalf of the Abbott Laboratories
Stock Retirement Trust does not constitute an admission that the undersigned is,
for purposes of Section 13(d) of the Securities and Exchange Act of 1934, the
beneficial owner of any securities covered by the Schedule. Pursuant to Rule
13d-4 of the Act, the undersigned disclaims such ownership with respect to any
shares listed therein of which he would not otherwise be deemed to be
beneficial owner.
/s/ Ellen M. Walvoord
---------------------------------------
Ellen M. Walvoord
February 9, 1996
---------------------------------------
Date